Tag: clinical trials

Aligning Issue Management With CAPA, Risk and Deviation Processes

Posted on By digi

Aligning Issue Management With CAPA, Risk and Deviation Processes In the clinical research environment, managing issues efficiently is critical to maintaining compliance with the regulatory requirements set forth by authorities such as the FDA, EMA, and MHRA. This article serves as a comprehensive guide for clinical operations, regulatory affairs, and medical affairs professionals who are…

Read More “Aligning Issue Management With CAPA, Risk and Deviation Processes” »

Issue Management & Escalation Paths

Escalation Triggers for Patient Safety, Data Integrity and Compliance Risks

Posted on By digi

Escalation Triggers for Patient Safety, Data Integrity and Compliance Risks Escalation Triggers for Patient Safety, Data Integrity and Compliance Risks Understanding the Importance of Escalation Triggers In the landscape of clinical trials, ensuring patient safety, data integrity, and compliance with regulatory guidelines is paramount. Escalation triggers are mechanisms put in place that notify clinical trial…

Read More “Escalation Triggers for Patient Safety, Data Integrity and Compliance Risks” »

Issue Management & Escalation Paths

Vendor and Cloud Provider Responsibilities for Data Integrity Controls

Posted on By digi

Vendor and Cloud Provider Responsibilities for Data Integrity Controls In the realm of clinical trials, ensuring data integrity is paramount to the success and regulatory compliance of research studies. With the increasing prevalence of cloud-based clinical trial solutions, understanding the responsibilities of vendors and cloud providers in maintaining data integrity controls is essential. This comprehensive…

Read More “Vendor and Cloud Provider Responsibilities for Data Integrity Controls” »

Data Integrity (ALCOA++, 21 CFR Part 11)

Risk Assessments Focused on Data Integrity and System Validation

Posted on By digi

Risk Assessments Focused on Data Integrity and System Validation Risk Assessments Focused on Data Integrity and System Validation In the landscape of clinical trials, data integrity and system validation emerge as critical elements that underpin the success and credibility of clinical research. This detailed guide aims to provide clinical operations, regulatory affairs, and medical affairs…

Read More “Risk Assessments Focused on Data Integrity and System Validation” »

Data Integrity (ALCOA++, 21 CFR Part 11)

Case Studies: Interim Analyses That Stopped Trials Early—for Good or Bad

Posted on By digi

Case Studies: Interim Analyses That Stopped Trials Early—for Good or Bad Case Studies: Interim Analyses That Stopped Trials Early—for Good or Bad Interim analyses play a crucial role in the management and evaluation of clinical trials. By analyzing data at predetermined intervals, researchers can make informed decisions about the continuation or termination of a trial….

Read More “Case Studies: Interim Analyses That Stopped Trials Early—for Good or Bad” »

Interim Analyses & Alpha Spending

Categorizing and Prioritizing Issues for Timely Response

Posted on By digi

Categorizing and Prioritizing Issues for Timely Response Categorizing and Prioritizing Issues for Timely Response In the realm of clinical trials, particularly in til therapy clinical trials, efficient management and resolution of arising issues are critical to maintaining compliance and ensuring the successful progression of studies. This article serves as a comprehensive guide for clinical operations,…

Read More “Categorizing and Prioritizing Issues for Timely Response” »

Issue Management & Escalation Paths

Governance Forums to Review and Decide on Critical Issues

Posted on By digi

Governance Forums to Review and Decide on Critical Issues Understanding Governance Forums in Clinical Trials The governance structure of clinical trials is essential for ensuring adherence to regulatory requirements and maintaining trial integrity. Governance forums offer a collaborative framework for clinical operations, regulatory affairs, and medical affairs professionals to assess and address critical issues arising…

Read More “Governance Forums to Review and Decide on Critical Issues” »

Issue Management & Escalation Paths

Data Flow Mapping to Identify Integrity Risks Across the Study Ecosystem

Posted on By digi

Data Flow Mapping to Identify Integrity Risks Across the Study Ecosystem Data Flow Mapping to Identify Integrity Risks Across the Study Ecosystem Data integrity in clinical trials is critical to ensuring the validity and reliability of trial results. With increasing regulatory scrutiny and the imperative to maintain compliance with established standards such as ALCOA++ and…

Read More “Data Flow Mapping to Identify Integrity Risks Across the Study Ecosystem” »

Data Integrity (ALCOA++, 21 CFR Part 11)

Handling Corrections, Late Entries and Data Changes in GCP Systems

Posted on By digi

Handling Corrections, Late Entries and Data Changes in GCP Systems Handling Corrections, Late Entries and Data Changes in GCP Systems The integrity of data in clinical trials is paramount for regulatory compliance, particularly under the guidelines of ICH-GCP, 21 CFR Part 11, and various other regulations established by authorities such as FDA, EMA, and MHRA….

Read More “Handling Corrections, Late Entries and Data Changes in GCP Systems” »

Data Integrity (ALCOA++, 21 CFR Part 11)

Regulatory Expectations for Interim Analyses in Pivotal Programs

Posted on By digi

Regulatory Expectations for Interim Analyses in Pivotal Programs Regulatory Expectations for Interim Analyses in Pivotal Programs Conducting clinical trials is a complex process governed by multiple regulatory frameworks, especially when it comes to pivotal programs. Among the many components of clinical trial design, interim analyses stand out as critical milestones. This article aims to provide…

Read More “Regulatory Expectations for Interim Analyses in Pivotal Programs” »

Interim Analyses & Alpha Spending